MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 17 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Targeting HER2 in Advanced Breast Cancer
Xiaofu Zhu, Anil A. Joy
2017· review· en· Methods in molecular biology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Trastuzumab-Associated Peripheral Vascular Toxicity
Gary Pansegrau, Dennis R. Grant, B. Norris, Karen A. Gelmon
2007· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
venueno affunlabeled
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes
Andreas Trojan, Sven Roth, Ziad Atassi, Michael K. Kießling, Reinhard Zenhaeusern, Yannick Kadvany +4 more
2024· article· en· JMIR Cancer· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Demonstration of Her-2 Protein in Cervical Carcinomas
Debra S. Heller, Meera Hameed, Seena C. Aisner, Bernadette Cracchiolo, Joan Skurnick, Diana Scott +1 more
2003· article· en· Journal of Lower Genital Tract Disease· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affno abstractunlabeled
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study
Konstantinos Tryfonidis, Sandrine Marréaud, Hussein Khaled, B. De Valk, Jan B. Vermorken, Marzena Wełnicka-Jaśkiewicz +5 more
2017· article· en· Breast Cancer Research and Treatment· Medicine
machine prediction:candidate · noneconsensus · none
4
citations

How this was built: Screen · Findings · About